References
- Amantana A, Moulton HM, Cate ML, et al. (2007). Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer. Bioconjugate Chem 18:1325–31.
- Barron LG, Kathleen B, Meyer B, et al. (1998). Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid-DNA complexes. Hum Gene Ther 9:315–23.
- Cao L, Han G, Lin C, et al. (2016). Fructose promotes uptake and activity of oligonucleotides with different chemistries in a context-dependent manner in mdx Mice. Mol Ther-Nucleic Acids 5:e329.
- Cirak S, Arechavala-Gomeza V, Guglieri M, et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:595–605.
- Evers MM, Toonen LJA, van Roon-Mom WMC. (2015). Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 87:90–103.
- Fletcher S, Honeyman K, Fall AM, et al. (2006). Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8:207–16.
- Goemans NM, Tulinius M, van den Akker JT, et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364:1513–22.
- Han G, Gu B, Cao L, et al. (2016). Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. Nat Commun 7:10981
- Technical Information about Luviquat Polymer Grades from BASF Chemical Company, May 2012. http://dewolfchem.com/wp-content/uploads/2013/08/Luviquat-TDS.pdf
- Hoffman EP, Brown RH Jr, Kunkel LM. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–28.
- Hoshino Y, Nakamoto M, Miura Y. (2012). Control of protein-binding kinetics on synthetic polymer nanoparticles by tuning flexibility and inducing conformation changes of polymer chains. J Am Chem Soc 134:15209–12.
- Hu Y, Wu B, Zillmer A, et al. (2010). Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo. Mol Ther 18: 812–18.
- Kendall GC, Mokhonova EI, Moran M, et al. (2012). Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci Transl Med 4:164ra160
- Kinali M, Arechavala-Gomeza V, Feng L, et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918–28.
- Koenig M, Beggs AH, Moyer M, et al. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498–506.
- Malerba A, Sharp PS, Graham IR, et al. (2011). Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther 19:345–54.
- Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. (2013). Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637–47.
- Nakamoto M, Hoshino Y, Miura Y. (2014). Effect of physical properties of nanogel particles on the kinetic constants of multipoint protein recognition process. Biomacromolecules 15:541–7.
- Reich C, Su DT. (2005). Cosmetic ingredients. In: André O. Barel, Howard I. Maibach, eds. Handbook of cosmetic science and technology. New York: Marcel Dekker, Inc., 331–46.
- Sakurai F, Nishioka T, Saito H, et al. (2001). Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: the role of the neutral helper lipid. Gene Ther 8:677–86.
- Sazani P, Kang SH, Maier MA, et al. (2001). Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res 29:3965–74.
- Summerton J, Weller D. (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187–95.
- van Deutekom JC, Janson AA, Ginjaar IB, et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677–86.
- Wang M, Wu B, Tucker JD, et al. (2015). Cationic polyelectrolyte-mediated delivery of antisense morpholino oligonucleotides for exon-skipping in vitro and in mdx mice. Inter J Nanomed 10:5638–46.
- Wu B, Cloer C, Shaban M, et al. (2012). Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol 181:392–400.
- Wu B, Li Y, Morcos PA, et al. (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 17:864–71.
- Wu B, Lu P, Benrashid E, et al. (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17:132–40.
- Wu B, Moulton HM, Iversen PL, et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105:14814–9.
- Yano J, Smyth GE. (2012). New antisense strategies: chemical synthesis of RNA oligomers. Adv Polym Sci 249:1–48.
- Yin H, Moulton HM, Seow Y, et al. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909–18.